Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a probiotic shield patients from Post-Surgery infections?

NCT ID NCT07792980

Disease control Sponsor: hy Co., LTD. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether the probiotic supplement MPRO3 can reduce infectious complications after colon cancer surgery. About 100 patients scheduled for colon cancer surgery will take either MPRO3 or a placebo capsule once daily for 13 weeks, starting one week before surgery. Researchers will compare infection rates, recovery measures, and changes in gut bacteria between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a probiotic mixture called MPRO3
What this could lead to
If MPRO3 works, it could offer a simple, safe way to lower infection risk and improve recovery after colon cancer surgery.
What could go wrong
This is a small, early-stage trial, and the results may not apply to all patients. Probiotics can occasionally cause digestive discomfort, and the benefit over placebo is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A person who is diagnosed histologically or radiologically with adenocarcinoma of the colon and is scheduled to undergo surgery Exclusion Criteria: * A person who has received chemotherapy or radiotherapy for colon cancer before surgery * A person with fecal incontinence * A person who has been diagnosed with an acute or serious disease, such as liver, kidney, heart, or thyroid disease, or is taking related medication * A person with alcohol dependence or a history of drug abuse * A person with immune system disorders, infectious diseases, or gastrointestinal diseases, including inflammatory bowel disease * A person who is currently diagnosed with or receiving treatment for another type of cancer * A person with renal dysfunction, defined as serum creatinine at least 1.5 times the upper limit of normal, or liver dysfunction, defined as AST and/or ALT at least 2.5 times the upper limit of normal * A person who has continuously used probiotics within the previous week * A person who is pregnant or lactating * A person who has hypersensitivity to the investigational product or any of its ingredients, or an allergy to a specific ingredient * A person who has participated in another human study or drug clinical trial within one month before the start of this study, except for a study involving only non-invasive surveys * A person who is unable to read letters or whose ability is limited * A person deemed inappropriate by the investigator to participate in this study for other reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Seoul ST. Mary's Hospital

    RECRUITING

    Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.